Mile­stone’s plans to re­sub­mit heart drug; Alvotech’s $166M of­fer; Vac­cine biotech rais­es $11M

Mile­stone Phar­ma­ceu­ti­cals de­tails plan to re­sub­mit etri­pamil to the FDA in Q2: For its ex­per­i­men­tal treat­ment for parox­ys­mal supraven­tric­u­lar tachy­car­dia, the com­pa­ny will now “re­struc­ture the da­ta sets” for tim­ing around ad­verse events and “re­for­mat cer­tain da­ta files” for FDA analy­ses. Mile­stone had re­port­ed a refuse-to-file ac­tion in De­cem­ber. Its stock $MIST was up about 22% on Mon­day morn­ing. — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER